1-6 of 6
Ming Gao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma

Qiang Li, Weituo Zhang, Tian Liao, Yi Gao, Yanzhi Zhang, Anqi Jin, Ben Ma, Ning Qu, Huan Zhang, Xiangqian Zheng, Dapeng Li, Xinwei Yun, Jingzhu Zhao, Herbert Yu, Ming Gao, Yu Wang, Biyun Qian
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 139–150.
https://doi.org/10.1158/1078-0432.CCR-24-2356
Published: 06 January 2025
View article titled, An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma
Open the PDF for An Artificial Intelligence–Driven Preoperative Radiomic Subtype for Predicting the Prognosis and Treatment Response of Patients with Papillary Thyroid Carcinoma in another window
Includes: Supplementary data
Journal Articles

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Yihebali Chi, Xiangqian Zheng, Yuan Zhang, Feng Shi, Ying Cheng, Zhuming Guo, Minghua Ge, Jianwu Qin, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiaohong Chen, Hui Liu, Ruochuan Cheng, Zhengang Xu, Dapeng Li, Pingzhang Tang, Ming Gao
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4047–4056.
https://doi.org/10.1158/1078-0432.CCR-22-3406
Published: 13 October 2023
View article titled, Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
Open the PDF for Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial in another window
Includes: Supplementary data
Journal Articles

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Xiangqian Zheng, Zhengang Xu, Qinghai Ji, Minghua Ge, Feng Shi, Jianwu Qin, Feng Wang, Guang Chen, Yuan Zhang, Rui Huang, Jian Tan, Tao Huang, Sijin Li, Zhongwei Lv, Yansong Lin, Zhuming Guo, Tomoki Kubota, Takuya Suzuki, Hiroki Ikezawa, Ming Gao
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5502–5509.
https://doi.org/10.1158/1078-0432.CCR-21-0761
Published: 15 October 2021
View article titled, A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Open the PDF for A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in another window
Includes: Supplementary data
Journal Articles

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Pingzhang Tang, Ming Gao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3567–3575.
https://doi.org/10.1158/1078-0432.CCR-20-2950
Published: 01 July 2021
View article titled, Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Open the PDF for Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial in another window
Includes: Supplementary data
Journal Articles

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu, Yali Zhou, Mingming Zhang, Wengang Ge, Yi Li, Li Yang, Guoqing Wei, Lu Han, Hao Wang, Shuhui Yu, Yi Chen, Yanbin Wang, Xiaohong He, Xingwang Zhang, Ming Gao, Jingjing Yang, Xiuju Li, Jiangtao Ren, He Huang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2764–2772.
https://doi.org/10.1158/1078-0432.CCR-20-3863
Published: 15 May 2021
View article titled, CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Open the PDF for CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, Barbara Bedogni
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 6039–6050.
https://doi.org/10.1158/1078-0432.CCR-19-2773
Published: 13 November 2020
View article titled, Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Open the PDF for Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma in another window
Includes: Supplementary data